Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 6,220,000 shares, a growth of 38.2% from the November 30th total of 4,500,000 shares. Based on an average daily volume of 2,280,000 shares, the short-interest ratio is presently 2.7 days.
Cabaletta Bio Price Performance
NASDAQ CABA traded down $0.05 during trading on Monday, reaching $2.24. 1,236,808 shares of the company’s stock were exchanged, compared to its average volume of 1,424,783. Cabaletta Bio has a fifty-two week low of $1.76 and a fifty-two week high of $26.35. The stock has a market capitalization of $109.48 million, a P/E ratio of -1.04 and a beta of 2.37. The business has a 50 day moving average price of $3.28 and a 200-day moving average price of $5.02.
Hedge Funds Weigh In On Cabaletta Bio
Several hedge funds and other institutional investors have recently made changes to their positions in CABA. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Cabaletta Bio in the third quarter valued at about $32,000. Point72 DIFC Ltd acquired a new stake in Cabaletta Bio in the third quarter worth $33,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Cabaletta Bio by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock valued at $44,000 after purchasing an additional 3,724 shares during the period. Intech Investment Management LLC bought a new position in shares of Cabaletta Bio during the 3rd quarter worth about $67,000. Finally, GSA Capital Partners LLP bought a new position in shares of Cabaletta Bio during the 3rd quarter worth about $127,000.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on Cabaletta Bio
About Cabaletta Bio
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
Recommended Stories
- Five stocks we like better than Cabaletta Bio
- What Are Dividend Achievers? An Introduction
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- With Risk Tolerance, One Size Does Not Fit All
- Micron: Why Now Is the Time to Be Brave
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.